


Key Note Forum



International Conference and Exhibition on Cancer Science & Therapy

15-17 August 2011 Las Vegas, USA






Dr. Michael Mingzhao Xing

Johns Hopkins University School of Medicine, USA

Dr. Mingzhao Xing, M.D., Ph.D., is Associate Professor of Medicine, Oncology and Cellular and Molecular Medicine, Co-Director of the Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine. Following his initial medical training at the Second Military Medical University in Shanghai, China, he obtained a Ph. D. degree in Physiology and Biophysics at Case Western Reserve University in Cleveland. He subsequently completed an internal medicine residency at the Greater Baltimore Medical Center and a clinical fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. Upon completing the fellowship, Dr. Xing was recruited to the faculty at the Division of Endocrinology and Metabolism of the Johns Hopkins Hospital. Dr. Xing serves on a number of national and international professional committees/panels, including, for example, National Institute of Health study sections, American Thyroid Association committees, several cancer research grant review panels in European counties. He also serves as

a member or editor on a number of subspecialty journals, such as Journal of Clinical Endocrinology and Metabolism, Endocrine-Related Cancer, and Thyroid. Dr. Xing practices clinical endocrinology as a subspecialty consultant and teaching attending at the Johns Hopkins Hospital while also conducting laboratory research as a physician scientist. His main clinical and research interest is in thyroid diseases, particularly thyroid tumors. Supported by the American Cancer Society and NIH R0-1 grants, his laboratory has been studying molecular, genetic and epigenetic mechanisms of thyroid cancer and their clinical translations. His team has published actively in these areas, particularly in relation to the MAP kinase and PI3K/Akt pathways. He is co-holder of a patent on the initial discovery and clinical characterization of the BRAF mutation in thyroid cancer. He has published more than 80 scientific articles. Among his professional recognitions/awards are the US FAMRI Clinical Innovator Award, Maryland Innovator Award, American Cancer Society RSG Award, and "America's Top Physician" recognition.




Dr. Mahin Khatami

National Cancer Institute, USA

Dr. Mahin Khatami immigrated to USA in 1969 after training in Chemistry (BS) and Science Education (MS) in Iran. She received her MA in Biochemistry from SUNY at Buffalo (1977) and Ph.D. in Molecular Biology from the University of Pennsylvania (UPA, 1980). Her postdoctoral framings were in physiology, protein chemistry and immunology at UVA, Fox Chase Cancer Center & UPenn. She became a Faculty of Medicine at Dept. Ophthalmology-UPA until 1992; and in collaboration with a team of scientists, under direction and support of John H Rockey, MD, Ph.D., she quickly earned her supervisory responsibilities on two major projects; cell/molecular biology of diabetic retinopathy/maculopathy and experimental models of acute and chronic inflammatory diseases. As a junior faculty, she was perhaps a most productive scientist in the country as she published 39 scientific articles and over 60 abstracts in conference proceedings in the

first decade of her academic career. Since 1998, at NCI/NIH, extension of her earlier discoveries on immunobiology of inflammatory diseases became closely relevant to her duties as Program Director-HSA for developing concepts for molecular diagnosis, prevention and therapy of cancer for large clinical trials (Prostate-Long-Colorectal-Ovarian) and designs of cohort clinical studies. Dr. Khatami has lectured internationally; served as scientific judge; consultant to pharmaceutical companies; research advisor; member of professional societies; editorial membership and reviewer activities; symposia organizer; president of Graduate Women In Science, Washington Chapter. Before retiring in 2009, her position title was Assistant Director for Technology Program Development, Office of Technology and Industrial Relations and Program Director-IMAT, Office of Director, NCI/NIH. She is currently Book Editor on Inflammatory Diseases.



Dr. Francois M. Vallete

INSERM and Universite de Nantes, France

Dr. François M. Vallette has completed his Ph.D at the age of 26 years from Paris VII University and did postdoctoral studies in the Department of Cell Biology of NYU Medical Center. Currently, he is the director of the Department of

Oncogenesis and Targeted Therapies in the Nantes Angers Cancer Research Center in France. He has published more than 80 papers in reputed journals and serving as associate or editorial board member in several journals.




Dr. Stephen W.J. Wang

Millennium Pharmaceuticals Inc, USA

Dr. Stephen Wang received his training in pharmaceutical sciences at the Texas Medical Center under Professor Ming Hu. Dr. Wang currently serves as a principal scientist in the department of Drug Metabolism and Pharmacokinetics at Millennium Pharmaceuticals in Cambridge MA. Previously, Dr. Wang served as a senior scientist in the department of Drug

Metabolism and Pharmacokinetics at Merck. Dr. Wang's research interests focus on the disposition of xenobiotics in an effort to improve bioavailability of chemopreventive agents. Dr. Wang has made significant contributions in the field with a consistent publication track record of over 25 manuscripts in peer-reviewed scientific journals and various book chapters.




Dr. Jimmy T. Efird

Brody School of Medicine, USA

Dr. J. T. Efird completed his Doctorate in Epidemiology at Stanford University School of Medicine. He currently is an Associate Professor at Brody School of Medicine, East Carolina University (ECU) and has a joint appointment as Epidemiologist/Chief Statistician in the Center for Health Disparities Research. Prior to joining

ECU, Dr. Efird was Director of the Biostatistics Facility at the John A. Burns School of Medicine (Honolulu, Hawaii) and an Associate Member of the Cancer Research Center of Hawaii. Dr. Efird's research interests include brain tumours, soft-tissue sarcomas, and HPV-related cancers.



Dr. Eugene P. Goldberg

University of Florida, USA

Dr. Goldberg FAIMBE, FBSE, joined the faculty of the University of Florida as the Biomedical Program of Excellence Professor in 1975. At Florida, as part in the Departments of Chemistry and Materials Science & Engineering, he helped establish intramural graduate programs in Polymer and Biomedical Sciences. He is now also affiliated with the University's Cancer Center and the Departments of Biomedical Engineering, Pulmonology, and Pharmacology & Therapeutics. His biomedical research interests and activities for the past 35 years have been diverse with strong focus on localized chemotherapy by direct intratumoral drug injection. Pioneering cancer therapy studies

were initiated in 1976 as a Visiting NIH Scientist and marked by a seminal 1978;38:1311 Lung Cancer paper on IT Chemoimmunotherapy. Subsequent research was devoted to enhancement of intratumoral chemotherapy using drug-loaded albumin and DNA nanomesospheres as reviewed in JPP 2002;54:159-180. Recent clinical research has been focused primarily on bronchoscopic intratumoral injection of chemotherapy with Drs. Seyhan and Firuz Celikoglu and Dr. Wolfgang Hohenforst-Schmidt as reported in Cancer Therapy 2008;6:545-552 and JPP 2010;62:287-295. Dr. Goldberg is the senior author of more than 425 published and presented papers and is on the editorial boards of numerous journals.



Dr. John Thompson

University of Waterloo, Canada. Senesco Technologies Inc., USA

Dr. Thompson received his PhD from University of Alberta and he is professor of Biology and Associate Vice-president, Research at the University of Waterloo, his research interests include Biochemistry and molecular biology of programmed cell death: the molecular basis of membrane deterioration in senescing and aging

tissues; comparative aspects of senescence and stress including the role of hormones and the involvement of free radicals; functional genomics of senescence and apoptosis. He is the Chief Scientific Officer for Senesco Technologies Inc., USA and a Fellow of the Royal Society of Canada.



Dr. Shymal Dilip Desai

LSU Health Sciences Center, USA

Dr. Desai obtained her Bachelor of Science and Master of Science in Biochemistry from University of Mumbai, India. She received her Doctorate in Biochemistry from the University of Mumbai, India. She did her post-doctoral fellowship at the UMDNJ-RWJMS in New Jersey USA. She was a faculty member in the Department of

Pharmacology at the UMDNJ/RWJMS till 2007. In 2007, she joined the LSUHSC as Assistant Professor in the Department of Biochemistry & Molecular Biology. She has published 20 papers in reputed journals. She currently serves on the editorial board of the three reputed journals.



Dr. Sudhakar Akul

Boys Town National Research Hospital, USA

Dr. Sudhakar Akulapalli (Akul) is the founder Director of Cell Signaling, Retinal and Tumor Angiogenesis Laboratory at Boys Town National Research Hospital, Associate Professor at Creighton University School of Medicine and University of Nebraska Medical Center, Omaha, NE, USA. He did his postdoctoral training at Harvard Medical School, Boston, MA, USA (2003). He has received Ph.D (2001), M.Phil (1997) and M.Sc (1995) degrees in life sciences from University of Hyderabad; and B.Sc in Biology from Silver Jubilee College (APRDC) Kurnool, SK University (1993) from India. He received President's fellowship (1992), GATE (1996) and CSIR (2007-2000) fellowships from Government of India. He received Mahindra & Mahindra Educational Award (2000) and Young Clinical Scientist Awards from Flight Attendant Medical Research Institute (FAMRI) in 2007 and 2010. He also received Bio-Bio Young Scientist Award from OMICS publishing group; Michael A.

O'Connor Young Investigator Award; RO1 grant Award from NIH/NCI and Research Scholar Grant Award from ACS (2010). He is serving as AIBS/NIH-RO1 Grant reviewer for DT study section. He has published more than 35 research articles in several top journals including Science, Cancer Cell, JCI, Blood, PNAS, Gastroenterology, Cancer Research, JBC, IOVS, JCST etc. He is serving as an Executive Editor, Editor and Editorial board member of reputed journals and is serving as a reviewer for 21 scientific journals including JCI, Blood, Circulation, Circulation Research, Cancer research, Clinical Cancer research etc. He was honored by giving a position as Keynote Speaker, Chairman, Co-chairman and organizing committee member for several international conferences including Bio-Bio-2009; Bio-Bio-2010; Anal-Bio2010; Biomarkers & Clinical Research 2010; Diabetes & metabolism 2010 etc.